RG6013: Phase I data

An open-label, dose-escalation, Japanese Phase I trial in 18 patients with severe hemophilia A with and without Factor Vlll (FVIII) inhibitors showed that once-weekly subcutaneous 0.3, 1 and 3 mg/kg d...